Brachytherapy
Volume 5, Issue 1 , Pages 1-4 , January 2006

High-dose-rate versus low-dose-rate monotherapy in the treatment of localized prostate cancer: The case for high-dose-rate monotherapy: An up and coming treatment option for low-risk prostate cancer

References 

  1. Jemal A, Thomas A, Murray T, et al. Cancer statistics 2002. CA Cancer J Clin. 2002;52:23–47
  2. Talcott JA, Manola J, Clark JA, et al. Time course and predictors of symptoms after primary prostate cancer therapy. J Clin Oncol. 2003;21:3979–3986
  3. Zelefsky MJ, Fuks Z, Hunt M, et al. High-dose intensity modulated radiation therapy for prostate cancer: Early toxicity and biochemical outcomes in 772 patients. Int J Radiat Oncol Biol Phys. 2002;53:1111–1116
  4. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: Results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002;53:1097–1105
  5. Stock RG, Stone NN, Tabert A, et al. A dose response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys. 1998;41:101–108
  6. Potters L, Cao Y, Calugaru E, et al. A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2001;50:605–614
  7. Galalae RM, Martinez AA, Mate T, et al. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2004;58:1048–1055
  8. Grimm PG, Blasko JB, Sylvester JE, et al. 10-year biochemical (prostate specific antigen) control of prostate cancer with 125I brachytherapy. Int J Radiat Oncol Biol Phys. 2001;51:31–40
  9. Sylvester JE, Blasko JB, Grimm PG, et al. Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: The Seattle experience. Int J Radiat Oncol Biol Phys. 2003;57:944–952
  10. Zelefsky M, Fuks Z, Chan H, et al. Ten-year results of dose escalation with 3-dimensional conformal radiotherapy for patients with clinically localized prostate cancer. Int J Radiol Oncol Biol Phys. 2003;57:S149;(abstract)
  11. Mate TP, Gottesman JE, Hatton J, et al. High-dose-rate afterloading 192 Iridium prostate brachytherapy: Feasibility report. Int J Radiat Oncol Biol Phys. 1998;41:525–533
  12. Sylvester J, Blasko J, Grimm P. Transrectal ultrasound guided prostate brachytherapy. In:  D'Amico A,  Loeffler JS,  Harris JR editor. Image-guided diagnosis and treatment of cancer. Totowa, NJ: Humana Press; 2003;p. 119–154
  13. Hoskin PJ, Bownes PJ, Ostler P, et al. High dose rate after loading brachytherapy for prostate cancer: Catheter and gland movement between fractions. Radiother Oncol. 2003;68:285–288
  14. Martinez AA, Pataki I, Edmundson G, et al. Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: A feasibility report. Int J Radiat Oncol Biol Phys. 2001;49:61–69
  15. Grills IS, Martinez AA, Hollander M, et al. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds. J Urol. 2004;171:1098–1104
  16. Yoshioka Y, Nose T, Yoshida K, et al. High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: Treatment description and preliminary results of a phase I/II clinical trial. Int J Radiat Oncol Biol Phys. 2000;48:675–681
  17. Davis JW, Kuban DA, Lynch DF, et al. Quality of life after treatment for localized prostate cancer: Differences based on treatment modality. J Urol. 2001;166:947–952

PII: S1538-4721(06)00003-1

doi: 10.1016/j.brachy.2006.01.001

Brachytherapy
Volume 5, Issue 1 , Pages 1-4 , January 2006

Article Tools

* Image Usage & Resolution